Clinical Trial: Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for AML Patients in First or Second CR
Brief Summary: Dendritic cells vaccinations are increasingly used in order to develop antitumoral immune response. This will be a Phase 2 trial using autologous dendritic cells pulsed with leukemic apoptotic corpse in acute myelogenous leukemia (AML) patients in first or second Complete remission (CR).
Detailed Summary:
Sponsor: Nantes University Hospital
Current Primary Outcome: Adverse events [ Time Frame: 6 weeks ]
Original Primary Outcome: Adverse events [ Time Frame: 6 weeks ]
Current Secondary Outcome:
- immune response [ Time Frame: Day 14 ]
- Complete remission [ Time Frame: 18 months ]
- Survival [ Time Frame: 18 months after injection ]Overall survival (from the documentation of the second RC)
Original Secondary Outcome:
Information By: Nantes University Hospital
Dates:
Date Received: June 16, 2010
Date Started: November 2009
Date Completion: April 2017
Last Updated: July 25, 2016
Last Verified: December 2015